Cite

HARVARD Citation

    Cahn, A. et al. (2020). Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study. Diabetes, obesity & metabolism. 22 (8), pp. 1357-1368. [Online]. 
  
Back to record